Sotyktu floundering

Quote




















anonymous said:
Uh, I think that’s why SALESPEOPLE are needed, not just “reps”.
Click to expand...

I understand why you’d reply that way, but I respectfully disagree. I didn’t create the drug, therefore can’t help it if the drug doesn’t respond well or the AE’s are more frequent or severe than our label leads on. The smoke and mirrors only last for so long before providers get some experience and realize it’s not as good as they hoped it would be. It’s not bad selling a niche drug, but I just don’t have the optimism for this drug that I had when we launched.
 
















anonymous said:
I understand why you’d reply that way, but I respectfully disagree. I didn’t create the drug, therefore can’t help it if the drug doesn’t respond well or the AE’s are more frequent or severe than our label leads on. The smoke and mirrors only last for so long before providers get some experience and realize it’s not as good as they hoped it would be. It’s not bad selling a niche drug, but I just don’t have the optimism for this drug that I had when we launched.
Click to expand...
Show us the AE profile relative to Jak inhibitors. It may sound like an informed slag by a professional, but you are talking out of your ass.
 




anonymous said:
Show us the AE profile relative to Jak inhibitors. It may sound like an informed slag by a professional, but you are talking out of your ass.
Click to expand...

Nah man, I have been ranked well through the launch of this drug. I know what I’m talking about. I never compared the AE profile to JAK’s. What I said was the inconsistency of the side effects was so broad that my physicians are deciding that the efficacy they are getting from deucra isn’t worth the unpredictability of the side effects. This is the experience from one territory, not country wide. If others aren’t having this issue and having success, lucky day, but someone posted a few days ago that the smart reps are already looking because they know this won’t last. You sound like the one rep bragging about 1-2 good quarters who is going to ride this out.

Best of luck to you
 




anonymous said:
Nah man, I have been ranked well through the launch of this drug. I know what I’m talking about. I never compared the AE profile to JAK’s. What I said was the inconsistency of the side effects was so broad that my physicians are deciding that the efficacy they are getting from deucra isn’t worth the unpredictability of the side effects. This is the experience from one territory, not country wide. If others aren’t having this issue and having success, lucky day, but someone posted a few days ago that the smart reps are already looking because they know this won’t last. You sound like the one rep bragging about 1-2 good quarters who is going to ride this out.

Best of luck to you
Click to expand...

Providers are not impressed with the product. There are several of us that are leaving soon. I talked to the Abbvie rep and she said there were several Sotyktu reps that have applied for the Rinvoq position as her partner.
 




anonymous said:
Nah man, I have been ranked well through the launch of this drug. I know what I’m talking about. I never compared the AE profile to JAK’s. What I said was the inconsistency of the side effects was so broad that my physicians are deciding that the efficacy they are getting from deucra isn’t worth the unpredictability of the side effects. This is the experience from one territory, not country wide. If others aren’t having this issue and having success, lucky day, but someone posted a few days ago that the smart reps are already looking because they know this won’t last. You sound like the one rep bragging about 1-2 good quarters who is going to ride this out.

Best of luck to you
Click to expand...
What do you call a sales rep who has no idea of how to argue data about an AE profile, nor sell a product, relative to the existing competitive landscape?
 












anonymous said:
Maybe the sales reps are not interested or incentivized to know anything. Or, maybe they are just lazy.
Click to expand...


Maybe we have been lied to repeatedly. We know we are going to get laid off. We sabotaged our relationships with providers lying about acne and folliculitis. It’s more common than we let on. Head to toe rashes are constant.
 




anonymous said:
Maybe we have been lied to repeatedly. We know we are going to get laid off. We sabotaged our relationships with providers lying about acne and folliculitis. It’s more common than we let on. Head to toe rashes are constant.
Click to expand...
More prevalent than trials statistcally argue? Or, are you pulling that out of thin air? Relative to GI for JAKs, what is the risk assessment between comparators? Do you know or are you only airing grievances?
 




anonymous said:
More prevalent than trials statistcally argue? Or, are you pulling that out of thin air? Relative to GI for JAKs, what is the risk assessment between comparators? Do you know or are you only airing grievances?
Click to expand...

I know what providers are telling me after their one and done trials. Look go to war for this drug if you want to. But I for one am tired.
 








anonymous said:
If you are tired go to sleep or quit the job because you are weak and can’t sell the drug.
Click to expand...

How many territories are meeting/exceeding the average new enrollments projected by BMS when Steven Jackson gave his presentation at the POA in Vegas? The number was 3.2 per week. Hint: you’ll only need one hand. I’ll wait as you count to 5….Buwahahaha
 




Top Bottom
Back
Quote